简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
Boan Biotech Announces 2025 Half-Year Results
2025.08.28
Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing
2025.08.08
Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert
2025.07.15
17
2025-06
Boan Receives FDA IND Clearance for Its CD228-Directed ADC
12
2025-06
Boan Grants Shaphar Right to Commercialize BA5101 in China
30
2025-04
Boan Biotech Presents Early Research Findings about Its Innovative Anti-CD25 Antibody (BA1106) at AACR Annual Meeting 2025
22
2025-04
Phase 3 Trial Results of Boan Biotech’s Dulagutide Injection Published in Journal of Diabetes
28
2025-03
Boan Biotech Announces 2024 Financial Results
27
2025-03
Boan Biotech's CD228 ADC Granted ODD by US FDA
20
2025-03
Boan Holds BPD Type 2b Meeting with FDA on BA1104
1
2
3
4
5
Follow me
鲁公网安备37069102000284